U.S. SUPREME COURT RULES AGAINST AMGEN'S BID TO REVIVE PATENTS ON ITS CHOLESTEROL DRUG REPATHA
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
285.6 USD | -0.25% | +3.19% | -0.78% |
Mar. 09 | Amgen Presents New Research on Otezla at AAD 2024 | CI |
Mar. 06 | Amgen Keeps Q2 Dividend at $2.25 a Share, Payable June 7 to Stockholders of Record May 17 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.78% | 153B | |
+34.94% | 701B | |
+26.24% | 571B | |
+1.05% | 381B | |
+20.83% | 334B | |
+17.06% | 319B | |
+0.89% | 210B | |
+2.83% | 210B | |
-6.26% | 201B | |
-3.13% | 157B |
- Stock
- Equities
- Stock Amgen Inc. - Nasdaq
- News Amgen Inc.
- U.s. Supreme Court Rules Against Amgen's Bid To Revive Patents O…